drugset / Trial / NCT00752661

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

NCT00752661

Phase 2 Completed 119 enrolled Janssen Pharmaceutical K.K.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the clinical dose range of an active ingredient of JNS013 - Tramadol hydrochloride in chronic-pain patients who cannot attain a sufficient analgesic effect from non-steroidal anti-inflammatory drugs (NSAIDs).

Timeline

Start
2007-06
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tramadol Other / unclassified 25 mg Oral
Subject Tramadol Other / unclassified 100 mg Oral

Indications